Status:
ENROLLING_BY_INVITATION
Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL
Lead Sponsor:
Chinese Academy of Medical Sciences
Conditions:
Diffuse Large B Cell Lymphoma
Eligibility:
All Genders
18-80 years
Brief Summary
The main objective of this study is to observe the overall survival of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in previously untreated subjects with CD20+ DLBCL. The secondar...
Detailed Description
1. Enrollment:407 subjects. 2. The inclusion criteria of this study: subjects who have participated in Phase III clinical trials.Phase III clinical trial（NCT02787239） has ended. 3. The exclusion crite...
Eligibility Criteria
Inclusion
- Subjects who have participated in Phase III study（NCT02787239）.
Exclusion
- ①Subjects died; ②Subjects are unwilling to participate in follow-up study; ③ the investigator judges that the subject is not suitable for participating the study.
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
407 Patients enrolled
Trial Details
Trial ID
NCT04491721
Start Date
July 1 2020
End Date
July 1 2027
Last Update
July 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, China